Full video transcriptClick to expand
Auto-generated transcript of @the.tudca.king's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The most common side effect I see people who are on testosterone replacement therapy deal with
- 0:05is having high hematocrit. The majority of people, even on TRT doses, will experience a raise in their
- 0:11hematocrit and hemoglobin, thickening their blood. And in a lot of cases, their doctor will take them
- 0:17off of the TRT prescription because they have no reliable way of controlling that hematocrit.
- 0:23When these patients go and donate blood, it typically causes their ferritin levels to crash,
- 0:27so that becomes too low and they are still forced to go and donate blood every few weeks.
- 0:32That's why our hematflow product has become a perfect solution for people who deal with this
- 0:37exact problem. Hemoflow will gradually bring your hematocrit levels under control, whether you're
- 0:42running TRT or running full-blown cycles. And it's really shame to see people who are forced to stop
- 0:48their TRT therapy because of this side effect that can be resolved by using something like hematflow.
- 0:55Because there are just so many positive benefits to being on a TRT therapy if you are someone who
- 1:00really needs it.
High hematocrit on TRT: when stopping is the right call
Quick answer
Testosterone-induced erythrocytosis affects an estimated 40-50% of men on TRT, making it the most frequently cited reason for dose reduction or discontinuation. Management is genuinely limited in clinical practice, with phlebotomy carrying iron depletion risk and formulation switching not always feasible. No dietary supplement has been validated in peer-reviewed trials to reduce testosterone-related hematocrit elevation, making the product claim in this video unsupported by current evidence.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For High hematocrit on TRT: when stopping is the right call, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
High hematocrit on TRT: when stopping is the right call is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "High hematocrit on TRT: when stopping is the right call" from Leviathan Nutrition. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Testosterone-induced erythrocytosis affects an estimated 40-50% of men on TRT, making it the most frequently cited reason for dose reduction or discontinuation.
The reason this review is not generic is the source wording and the canonical claim label "trt trt stopped due to high hematocrit trt testosterone." In this clip, the useful excerpt is: "The most common side effect I see people who are on testosterone replacement therapy deal with is having high hematocrit." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Testosterone-induced erythrocytosis affects an estimated 40-50% of men on TRT, making it the most frequently cited reason for dose reduction or discontinuation.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Testosterone-induced erythrocytosis affects an estimated 40-50% of men on TRT, making it the most frequently cited reason for dose reduction or discontinuation. Management is genuinely limited in clinical practice, with phlebotomy carrying iron depletion risk and formulation switching not always feasible. No dietary supplement has been validated in peer-reviewed trials to reduce testosterone-related hematocrit elevation, making the product claim in this video unsupported by current evidence.
- Roughly 40-50% of men on testosterone therapy develop clinically elevated hematocrit, making this the most common reason for TRT dose reduction or discontinuation per current endocrinology literature.
- Repeated blood donation to manage hematocrit is a real clinical tradeoff: it works short-term but can deplete ferritin, sometimes to symptomatic levels, requiring careful monitoring.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Roughly 40-50% of men on testosterone therapy develop clinically elevated hematocrit, making this the most common reason for TRT dose reduction or discontinuation per current endocrinology literature.
- Repeated blood donation to manage hematocrit is a real clinical tradeoff: it works short-term but can deplete ferritin, sometimes to symptomatic levels, requiring careful monitoring.
- Transdermal testosterone formulations produce smaller hematocrit increases than injectable forms, according to a 2010 systematic review by Fernandez-Balsells et al. in Annals of Internal Medicine.
- No dietary or over-the-counter supplement has been validated in peer-reviewed randomized trials to reduce testosterone-induced erythrocytosis. Hematflow is not an exception based on available evidence.
- The Endocrine Society recommends hematocrit monitoring at 3 months and 6 months after starting TRT, then annually, with dose adjustment or formulation change if hematocrit exceeds 54%.
- Supraphysiologic anabolic steroid use and medically supervised TRT carry different risk profiles and should not be treated as interchangeable when discussing side effect management.
- If a physician discontinued your TRT over hematocrit concerns, the appropriate next step is a referral to an endocrinologist or hematologist, not a supplement protocol found on social media.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @the.tudca.king actually say?
The creator claims that high hematocrit is the most common TRT side effect, that doctors frequently pull patients off testosterone because they lack tools to manage it, and that blood donation as a fix causes ferritin to crash. Then comes the pitch: a supplement called Hematflow (referred to interchangeably as 'hemoflow') will 'gradually bring your hematocrit levels under control' whether someone is on TRT or 'full-blown cycles.'
The first half of the video contains several statements that are at least partially grounded in clinical reality. The second half pivots into supplement marketing dressed up as medical advice. The product claim, that an unnamed supplement can reliably control erythrocytosis in people using supraphysiologic testosterone doses, is unsupported by any published evidence presented here or, to our knowledge, anywhere.
Does the science back this up?
On erythrocytosis being common on TRT: yes, the data are pretty clear on this. Studies suggest roughly 40-50% of men on testosterone therapy develop hematocrit above 50%, depending on dose, formulation, and individual response.
Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) demonstrated a dose-dependent relationship between testosterone and erythropoiesis, showing that even replacement-level doses raise hemoglobin and hematocrit meaningfully. Bachman et al. (2010, JCEM) confirmed that older men are at higher risk. So the creator is not wrong that hematocrit elevation is widespread among TRT users.
On ferritin crashing after donation: this is also documented. Repeated phlebotomy depletes iron stores, and iron-deficiency without anemia is a real consequence for TRT patients who donate frequently. Gourna Paleoudis et al. (2021, Journal of Medical Case Reports) described this exact scenario in TRT patients managed with phlebotomy.
On Hematflow controlling hematocrit: there is no peer-reviewed evidence presented or publicly available supporting this specific product claim.
What did they get wrong (or right)?
Credit where it is due: the creator accurately identifies a real clinical problem. Erythrocytosis is the leading reason men discontinue TRT, and the current management options, mainly dose reduction, switching to topical formulations, or phlebotomy, each carry drawbacks. Doctors genuinely struggle with this.
What they got wrong, and got wrong significantly, is implying that their supplement is a validated solution for this problem. The phrase 'perfect solution' is marketing language, not clinical language. No supplement has been shown in randomized controlled trials to reduce testosterone-induced erythrocytosis. Some practitioners have explored low-dose aspirin or ACE inhibitors for related cardiovascular risk, but those are physician-managed interventions, not over-the-counter products.
Also concerning: the creator groups TRT patients with people running 'full-blown cycles,' meaning supraphysiologic anabolic steroid use. These are categorically different populations with different risk profiles. Treating them as interchangeable in a health context is misleading and potentially dangerous.
What should you actually know?
If your hematocrit is rising on TRT, this is a real issue worth taking seriously. Hematocrit above 54% is associated with increased blood viscosity, and some observational data link severe erythrocytosis to elevated cardiovascular risk, though causality is debated. The Endocrine Society guidelines recommend monitoring hematocrit at 3 and 6 months after starting TRT and annually thereafter.
Management options that have actual clinical backing include switching from injectable to transdermal testosterone, which tends to produce smaller hematocrit increases (Fernandez-Balsells et al., 2010, Annals of Internal Medicine), dose reduction, and therapeutic phlebotomy when necessary. Your prescribing physician can also consider whether secondary causes of erythrocytosis, like sleep apnea, are contributing.
No supplement should be your primary intervention for an out-of-range hematocrit. If a doctor stopped your TRT over this, the right move is a conversation with a hematologist or an endocrinologist, not a TikTok supplement.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Leviathan Nutrition · TikTok creator
1.1M views on this video
TRT stopped due to high hematocrit #trt #testosterone
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about roughly 40-50% of men on testosterone therapy develop clinically elevated?
Roughly 40-50% of men on testosterone therapy develop clinically elevated hematocrit, making this the most common reason for TRT dose reduction or discontinuation per current endocrinology literature.
What does the video say about repeated blood donation to manage hematocrit?
Repeated blood donation to manage hematocrit is a real clinical tradeoff: it works short-term but can deplete ferritin, sometimes to symptomatic levels, requiring careful monitoring.
What does the video say about transdermal testosterone formulations produce smaller hematocrit increases than injectable forms,?
Transdermal testosterone formulations produce smaller hematocrit increases than injectable forms, according to a 2010 systematic review by Fernandez-Balsells et al. in Annals of Internal Medicine.
What does the video say about no dietary?
No dietary or over-the-counter supplement has been validated in peer-reviewed randomized trials to reduce testosterone-induced erythrocytosis. Hematflow is not an exception based on available evidence.
What does the video say about the endocrine society recommends hematocrit monitoring at 3 months?
The Endocrine Society recommends hematocrit monitoring at 3 months and 6 months after starting TRT, then annually, with dose adjustment or formulation change if hematocrit exceeds 54%.
What does the video say about supraphysiologic anabolic steroid use?
Supraphysiologic anabolic steroid use and medically supervised TRT carry different risk profiles and should not be treated as interchangeable when discussing side effect management.
Sources & references
- [1]Coviello et al. (2008)
- [2]Bachman et al. (2010)
- [3]Paleoudis et al. (2021)
- [4]Fernandez-Balsells et al., 2010
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Leviathan Nutrition, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.